



## **SUGGESTED FORMULA**

Ibuprofen 4%/Clonidine 2%/Gabapentin 10%/Lidocaine 2.5%/Prilocaine 2.5% in Liposome Heavy Cream

Version number: 1.0

Volume or quantity: 240gm

Ibuprofen,USP (IB100)	9.6gm
Clonidine HCL, USP (CL118)	4.8gm
Gabapentin, USP (G1092)	24gm
Lidocaine, USP (LI102)	6gm
Prilocaine, USP (P1954)	6gm
Alcohol 190 Proof, USP (ET108)	XmL
Base, Liposome Heavy (B3192)	q.s. 240gm

## **SUGGESTED COMPOUNDING PROCEDURES**

Weigh all ingredients

- 1. Check calculations and gather all materials needed for the compound
- 2. Weigh and/or measure all ingredients
- 3. Crush and Triturate all tablets until fine powder, if needed pass through sieve
- 4. Add remaining dry chemicals and mix
- 5. Add enough Alcohol to powder mixture and triturate until a smooth paste is formed
- 6. Geometrically incorporate the Liposome-Heavy Base until a smooth homogenous mixture
- 7. May use an Electronic Mortar and Pestle and/or ointment mill to mix and reduce particle size
- 8. Transfer to appropriate container click jar, syringe, tube or jar
- 9. Suggested Quality assessments:
  - a. color
  - b. texture
  - c. container
  - d. Label auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at controlled room temperature.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products,

organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be assigned based on the current USP <795> Standards

**General:** Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

7/18 JD